1. Alagaratnam J, Bakewell N, Kunisaki KM, Mallon PWG, et al.
   Associations between plasma biomarkers and changes in cognitive function over two years in people with and without HIV.
   AIDS 2025.
   


2. Blankenberger J, Devendra A, Bakaya M, Lee T, et al.
   Tolerability of lopinavir versus dolutegravir in children and adolescents with HIV (LoDoCA): a prospective cohort study in lesotho, Southern Africa.
   AIDS 2025.
   


3. Sheng Q, Olumefun S, Peter O, Akhigbe P, et al.
   Cognitive performance in adolescents with perinatally-acquired HIV and associations with oral health in Nigeria.
   AIDS 2025.
   


4. Scheier TC, De Gouveia K, Engel ME, Hohlfeld AS, et al.
   One-year mortality among adults with advanced HIV in sub-Saharan Africa: a systematic review and meta-analysis.
   AIDS 2025.
   


5. Flick RJ, Masiano SP, Tembo TA, Sykes C, et al.
   Novel application of DBS tenofovir diphosphate to predict viral suppression in postpartum women living with HIV in Malawi.
   AIDS 2025.
   


6. Shilabye PS, Scheuermaier K, Umunnakwe CN, Barth RE, et al.
   HIV and ART status at baseline are associated longitudinally with increased pulse wave velocity: findings from the Ndlovu cohort study.
   AIDS 2025.
   


7. Willemstein IJM, Prins M, Wijstma E, Van Sighem A, et al.
   Estimating the HIV PrEP care continuum among gay, bisexual and other men who have sex with men in Amsterdam and the Netherlands, 2023.
   AIDS 2025.
   


8. Padilla S, Ledesma C, Fernandez-Gonzalez M, Perez-Calvo F, et al.
   Point-of-care ultrasound guidance for long-acting cabotegravir-rilpivirine administration improves injection-site tolerability and preserves pharmacokinetics.
   AIDS 2025.
   


9. Plaisy MK, Mondoka C, Moreira R, Samala N, et al.
   Diagnostic value of serological scores for the detection of liver steatosis in people living with HIV in low- and middle-income countries.
   AIDS 2025.
   


10. Murnane PM, Bukusi EA, Otieno P, Frongillo EA, et al.
    Effects of an agricultural intervention on psychosocial health among pregnant and non-pregnant women with HIV in Kenya.
    AIDS 2025.
    


11. Williams A, Adungo F, Ramirez JL, Oriol-Mathieu V, et al.
    The role of subtyping methodologies in HIV surveillance and vaccine development: a systematic review and meta-analysis.
    AIDS 2025.
    


12. Marcelin AG, Soulie C, Wirden M, Gruber J, et al.
    Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimens.
    AIDS 2025.
    


13. Agarawal S, Samanta J, Chauhan RS, Kathrani N, et al.
    Paradoxical tuberculosis-immune reconstitution inflammatory response syndrome after antituberculous drug modification in HIV with dual central nervous system infections.
    AIDS 2026;40:267-269.
    


14. MacBain E, Conroy AL, Brophy J, Kakkar F, et al.
    Chitinase-3-like 1 is associated with stunting and developmental delay in HIV-exposed but uninfected Ugandan children.
    AIDS 2026;40:263-266.
    


15. Apoliano CF, de Oliveira ACS, Folgosi VA, Prates GS, et al.
    Elevated sCD14 in cerebrospinal fluid: a surrogate marker for HIV-associated neurocognitive disorders in Brazil.
    AIDS 2026;40:260-263.
    


16. Woolley IJ.
    Hyping up hypertension and HIV.
    AIDS 2026;40:254-255.
    


17. Wood BR.
    Doravirine/islatravir for heavily treatment-experienced adults with HIV: promise interrupted.
    AIDS 2026;40:252-253.
    


18. Kuhn L, Brennan AT.
    No cause for complacency regarding health of children who are HIV-exposed but uninfected.
    AIDS 2026;40:249-251.
    


19. Yadav A, Stephens-Shields AJ, Karaj A, Kossenkov AV, et al.
    Galantamine for 12 weeks does not improve neurocognition or immune activation in ART-suppressed people with HIV.
    AIDS 2025.
    


20. Zhu B, Wang X, Li H, Liu Y, et al.
    Identification of a Novel HIV-1 Second-Generation Circulating Recombinant Form (CRF193_0107) Among MSM in Hebei Province, China.
    AIDS Res Hum Retroviruses 2025.
    


21. Oursler KK, Sun YV, Lozano AJ, Xu K, et al.
    Epigenetic Age Acceleration and Frailty Among People with HIV.
    AIDS Res Hum Retroviruses 2025.
    


22. Chen M, Chen H, Ma Y, Jia M, et al.
    Identification of a Novel HIV-1 Circulating Recombinant Form (CRF184_BC) Among Heterosexual Populations Along the China-Myanmar Border Region.
    AIDS Res Hum Retroviruses 2025.
    


23. Sabu P, Alex D, Ramalingam VV, Demosthenes JP, et al.
    Comparison of Plasma, Dried Blood Spots, and Peripheral Blood Mononuclear Cells as Biosamples for HIV-1 Genotypic Drug Resistance in a Tertiary Care Center.
    AIDS Res Hum Retroviruses 2025.
    


24. Bavi M, Jalilian S, Bijanzadeh M, Nashibi R, et al.
    Frequency of CCR5-Delta32, CCR2-64I, and SDF1-3'A Mutations in People with HIV Diagnoses and HIV Negative Participant in Khuzestan Province, Iran.
    AIDS Res Hum Retroviruses 2025.
    


25. Zhu Y, Liu J, Kang L, Ruan F, et al.
    HCV Genotype Distribution and Molecular Characteristics of HCV Core Domain I in Persons Living with HIV and HCV from Yunnan Province, China.
    AIDS Res Hum Retroviruses 2025.
    


26. Ahmed A, Dong KL, Hussain M, Ngcobo MW, et al.
    Psychological Impact of Analytical Treatment Interruption on Young Women Enrolled in an HIV Cure-Related Clinical Trial in Durban, South Africa.
    AIDS Res Hum Retroviruses 2025.
    


27. Colson AE, Crofoot GE, Ruane PJ, Ramgopal MN, et al.
    Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
    Ann Intern Med 2025.
    


28. Osuala EC, Nkuhairwe IN, Letsoalo MP, Naidoo K, et al.
    Pharmacokinetics of Twice-Daily Tenofovir Alafenamide In Adults with HIV-Associated TB on BIC/FTC/TAF and Rifampicin.
    Clin Infect Dis 2025.
    


29. Ignacio RB, Pagkas-Bather J, Gonsalves G, Gianella S, et al.
    Why Americans are Dying Younger? NIH Is Not the Problem. Our Broken Healthcare Delivery Is.
    Clin Infect Dis 2025.
    


30. Baltrusaitis K, Tierney C, Fowler MG, Owor M, et al.
    Postpartum maternal monitoring for renal safety related to tenofovir exposure during breastfeeding in the PROMISE 1077BF randomized trial.
    J Acquir Immune Defic Syndr 2025.
    


31. Ruderman SA, Fahey CA, Delaney JA, Kyle R, et al.
    Frailty and All-Cause Mortality among People with HIV Engaged in Clinical Care in the United States.
    J Acquir Immune Defic Syndr 2025.
    


32. Kang M, Umbleja T, Avihingsanon A, Cardoso SW, et al.
    Hepatitis B Vaccination Histories in Persons with HIV Needing Revaccination.
    J Acquir Immune Defic Syndr 2025.
    


33. Apornpong T, Do TC, Han WM, Hiranburana N, et al.
    Letter to the Editor Burden of Pre-Frailty and Frailty in older People with and without HIV in Thailand.
    J Acquir Immune Defic Syndr 2025.
    


34. Serti E, Bartolanzo D, Frndak S, Owuoth J, et al.
    Loss to Follow up and Visit Non-Adherence in an HIV Incidence Cohort in Kisumu, Kenya.
    J Acquir Immune Defic Syndr 2025.
    


35. Selzer L, Cai A, Poosarla A, Li J, et al.
    Association of HIV Envelope Susceptibility Signatures to Broadly Neutralizing Antibodies and Presence of p24 CTL Epitopes During Acute HIV-1 Infection.
    J Acquir Immune Defic Syndr 2025.
    


36. Walker CF, Lee MT, Chen PL, Ridgeway K, et al.
    Real-World Estimates of HIV Incidence from Sexual Health Clinic EMRs: Feasibility, Limitations, and Implications for Surveillance.
    J Acquir Immune Defic Syndr 2025.
    


37. Peterson JJ, Chandel S, James K, Bennett ES, et al.
    Single cell characterization of the gastrointestinal HIV reservoir reveals heterogeneous cellular phenotypes.
    J Clin Invest 2025.
    


38. Anjum SH, Hargarten J, Dulek B, Otaizo-Carrasquero F, et al.
    Cerebral Venous Thrombosis in Previously Healthy Patients with Cryptococcal Meningitis.
    J Infect Dis 2025.
    


39. McCarthy WJ, Ferguson F, Gelberg L.
    For Optimal HIV Viral Load Reduction, Increase Intake of Gut Microbe-Friendly Foods: Comment on Palar et al.
    J Infect Dis 2025;232:e1060-e1061.
    


40. Ignacio RB, Pagkas-Bather J, Gonsalves G, Gianella S, et al.
    Why Americans are Dying Younger? NIH Is Not the Problem. Our Broken Healthcare Delivery Is.
    J Infect Dis 2025.
    


41. Lagi F, Formica G, Fabbiani M, Rossetti B, et al.
    Durability of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Adults Living With HIV: A Multicenter Observational Cohort in Tuscany (LAHIV).
    J Med Virol 2026;98:e70779.
    


42. El Khalili O, Chenwi CA, Spalletta D, Marchegiani G, et al.
    Development of a Next-Generation Sequencing Protocol for Assessing Lenacapavir Resistance in HIV-1 Capsid.
    J Med Virol 2026;98:e70773.
    


43. Xiao J, Wang F, Zhu L, Liu Y, et al.
    Residual Exhaustion of Stem Cell-Like Memory T Cells (T(SCM)) in HIV Infected Patients With Viral Suppression.
    J Med Virol 2025;97:e70761.
    


44. Kreig JAF, Wahl A, Fernandes E, Honeycutt JB, et al.
    The decay of HIV under anti-retroviral therapy is biphasic even in humanized mice with just T cells.
    J Virol 2025.
    


45. Vakaniaki EH, Barhishindi I, Mubiala A, Malembaka EB, et al.
    Maternal and neonatal outcomes after infection with monkeypox virus clade I during pregnancy in DR Congo: a pooled, prospective cohort study.
    Lancet 2025.
    


46. Green A.
    Botswana's HIV services struggle.
    Lancet 2025.
    


47. Huynh J, Le NHT, Le Nguyen BH, Hoang HT, et al.
    The Utility of a Three-gene Host Response to Discriminate Tuberculous Meningitis From Other Infections in Children.
    Pediatr Infect Dis J 2025.
    

Display articles in

• Abstract format